Scinai Immunotherapeutics Ltd.(SCNI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.3M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SCNI Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Scinai Immunotherapeutics Ltd. (SCNI), a Healthcare sector company. SCNI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Scinai Immunotherapeutics Ltd. reports quarterly revenue of $1.3M, net income of $-8.3M, free cash flow of $-6.1M. Top institutional holders of SCNI by reported 13-F value include CITADEL ADVISORS, ARMISTICE CAPITAL, Virtu Financial, based on the most recent SEC filings. SCNI trades on the Nasdaq exchange and files with the SEC under CIK 1611747. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCNI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scinai Immunotherapeutics Ltd. directly from SEC EDGAR.
Revenue
FY 2025
$1.3M
Net Income
FY 2025
$-8.3M
Free Cash Flow
FY 2025
$-6.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+99.2% YoYNet Income
-273.2% YoYOperating Income
+12.7% YoYEPS (Diluted)
Total Assets
-13.5% YoYTotal Debt
Op. Cash Flow
+4.8% YoYFree Cash Flow
+4.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.3M +99.2% | $658.0K | — | — | — | — |
| Net Income | $-8.3M -273.2% | $4.8M +173.8% | $-6.5M -12.1% | $-5.8M +29.4% | $-8.2M | — |
| Operating Income | $-7.5M +12.7% | $-8.6M +11.0% | $-9.7M +12.3% | $-11.1M -1.8% | $-10.9M | — |
| EPS (Diluted) | — | — | $0.00 -60.0% | $0.01 +150.0% | $-0.02 | — |
| Total Assets | $11.6M -13.5% | $13.4M -23.0% | $17.5M -35.4% | $27.1M -15.5% | $32.0M -43.7% | $56.9M |
| Total Debt | — | — | — | $382.0K +1.9% | $375.0K | — |
| Operating Cash Flow | $-6.0M +4.8% | $-6.3M +32.5% | $-9.4M -29.1% | $-7.3M +2.2% | $-7.4M | — |
| Free Cash Flow | $-6.1M +4.6% | $-6.3M +36.7% | $-10.0M -23.7% | $-8.1M -7.1% | $-7.6M | — |
Get alerted when SCNI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Scinai Immunotherapeutics Ltd. including:
Top Institutional Holders of SCNI
CITADEL ADVISORS LLC
$15.7K62,257 shARMISTICE CAPITAL, LLC
$9.1K35,942 shVirtu Financial LLC
$5.0K19,485 shStoneX Group Inc.
$4.6K13,092 shXTX Topco Ltd
$4.2K16,764 shRHUMBLINE ADVISERS
$3.4K13,513 shCAPTRUST FINANCIAL ADVISORS
$3.0K12,035 shUBS Group AG
$1.0K3,955 shMORGAN STANLEY
$15.0058 shHRT FINANCIAL LP
$3.0012,088 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $15.7K | 62,257 |
| ARMISTICE CAPITAL, LLC | $9.1K | 35,942 |
| Virtu Financial LLC | $5.0K | 19,485 |
| StoneX Group Inc. | $4.6K | 13,092 |
| XTX Topco Ltd | $4.2K | 16,764 |
| RHUMBLINE ADVISERS | $3.4K | 13,513 |
| CAPTRUST FINANCIAL ADVISORS | $3.0K | 12,035 |
| UBS Group AG | $1.0K | 3,955 |
| MORGAN STANLEY | $15.00 | 58 |
| HRT FINANCIAL LP | $3.00 | 12,088 |
More Healthcare Companies
View all Healthcare →Put SCNI on your watchlist
Track score changes the day Scinai Immunotherapeutics Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SCNI a good stock to buy?
13F Pro's AI-powered analysis of Scinai Immunotherapeutics Ltd. (SCNI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCNI are available on the SCNI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SCNI is classified as a large company.
Which hedge funds own SCNI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCNI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Scinai Immunotherapeutics Ltd.'s investment landscape.